2,4-Diaminoquinazolines as antithrombotic agents
AssigneeEli Lilly and Company
InventorWilliam B. Lacefield
Life of this patent
Estimating the term…
Loading patent…
AssigneeEli Lilly and Company
InventorWilliam B. Lacefield
Estimating the term…
2,4-Diaminoquinazolines are employed as antithrombotic agents and have the following general formula: ##STR1## wherein R.sub.1 and R.sub.2 are monovalent groups independently selected from the group consisting of A. ##STR2## wherein R.sub.4 and R.sub.5 independently are selected from the group consisting of hydrogen, alkyl, and cycloalkyl, with the proviso that both R.sub.4 and R.sub.5 cannot be cycloalkyl, B. ##STR3## wherein R.sub.6, R.sub.7, and R.sub.8 independently are selected from the group consisting of hydrogen and alkyl, and A is a divalent organic group having from two to about six carbon atoms such that the two nitrogen atoms are separated by at least two carbon atoms, and C. heterocyclic-amino, and R.sub.3 is a monovalent group selected from the group consisting of hydrogen, halogen, and alkyl.
A method of inhibiting platelet aggregation in a warm-blooded animal in need of such inhibition which comprises parenterally administering to said animal an effective and nontoxic amount of a compound of the formula, ##STR56## wherein R.sub.1 and R.sub.2 are monovalent groups independently selected from the group consisting of
A method of inhibiting platelet aggregation in a warm-blooded animal in need of such inhibition which comprises parenterally administering to said animal an effective and non-tonic amount of a compound of the formula, ##STR59## wherein R.sub.1 and R.sub.2 are monovalent groups independently selected from the group consisting of
A method of inhibiting platelet aggregation in a warm-blooded animal in need of such inhibition which comprises parenterally administering to said animal an effective and nontoxic amount of a compound of the formula, ##STR62## wherein R.sub.1 and R.sub.2 are monovalent groups independently selected from the group consisting of
The method of inhibiting platelet aggregation in a warm-blooded animal in need of such inhibition which comprises enterally administering to said animal an effective and nontoxic amount of 2-morpholino-4-(2-diethylaminoethylamino) quinazoline and physiologically-acceptable salts thereof.
Dependencies are inferred from the claim text.